Fortress Biotech, Inc. (NASDAQ:FBIO – Get Free Report) CFO David Jin purchased 15,000 shares of the stock in a transaction on Tuesday, November 17th. The shares were bought at an average cost of $1.72 per share, for a total transaction of $25,800.00. Following the transaction, the chief financial officer directly owned 1,667,761 shares in the company, valued at approximately $2,868,548.92. The trade was a 0.91% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
David Jin also recently made the following trade(s):
- On Thursday, November 19th, David Jin acquired 7,605 shares of Fortress Biotech stock. The stock was bought at an average cost of $1.87 per share, with a total value of $14,221.35.
- On Wednesday, November 18th, David Jin acquired 25,000 shares of Fortress Biotech stock. The stock was bought at an average cost of $1.91 per share, with a total value of $47,750.00.
Fortress Biotech Trading Up 7.3%
NASDAQ FBIO opened at $1.90 on Friday. Fortress Biotech, Inc. has a 12 month low of $1.64 and a 12 month high of $4.53. The company has a current ratio of 2.93, a quick ratio of 3.83 and a debt-to-equity ratio of 0.10. The stock has a 50 day moving average of $2.06 and a 200-day moving average of $2.69. The company has a market cap of $64.11 million, a PE ratio of 0.83 and a beta of 1.27.
Fortress Biotech (NASDAQ:FBIO – Get Free Report) last issued its earnings results on Friday, November 13th. The biopharmaceutical company reported ($0.23) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.04. Fortress Biotech had a net margin of 143.04% and a return on equity of 61.84%. The business had revenue of $19.16 million for the quarter, compared to the consensus estimate of $21.57 million. On average, equities research analysts anticipate that Fortress Biotech, Inc. will post 2.66 EPS for the current fiscal year.
Institutional Investors Weigh In On Fortress Biotech
Hedge funds and other institutional investors have recently modified their holdings of the company. Marshall Wace LLP acquired a new position in shares of Fortress Biotech in the third quarter valued at about $462,000. Renaissance Technologies LLC increased its position in Fortress Biotech by 22.8% during the first quarter. Renaissance Technologies LLC now owns 99,590 shares of the biopharmaceutical company’s stock worth $278,000 after acquiring an additional 18,490 shares during the period. Finally, Squarepoint Ops LLC bought a new position in Fortress Biotech during the second quarter worth about $47,000. Institutional investors and hedge funds own 96.51% of the company’s stock.
Top Fortress Biotech Stories
Here are a few of the latest stories about FBIO:
- Positive Sentiment: CEO Lindsay Rosenwald and CFO David Jin bought a combined 184,328 shares from November 17–19, investing approximately $340,000. These purchases increased their existing holdings and may signal confidence, although insider buying does not guarantee improving business fundamentals. Insider buying report
- Neutral Sentiment: Zacks Research initiated coverage with a “hold” rating, offering no clear directional signal for the shares. Zacks rating information
- Negative Sentiment: HC Wainwright forecasts EPS of $2.37 for FY2027, below its $2.66 estimate for FY2026. The estimates are not company guidance, but the year-over-year decline could temper optimism. Earnings estimate report
Wall Street Analysts Forecast Growth
Several brokerages recently issued reports on FBIO. Weiss Ratings downgraded shares of Fortress Biotech from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 23rd. Zacks Research initiated coverage on Fortress Biotech in a research report on Wednesday. They set a “hold” rating on the stock. Finally, Wall Street Zen lowered Fortress Biotech from a “strong-buy” rating to a “hold” rating in a research note on Saturday, August 15th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Fortress Biotech presently has an average rating of “Hold” and an average target price of $17.00.
Get Our Latest Analysis on Fortress Biotech
Fortress Biotech Company Profile
Fortress Biotech, Inc. is a biopharmaceutical company that develops and commercializes prescription medicines through a network of subsidiaries and affiliated companies. Its approach includes advancing drug candidates, acquiring or licensing development and commercialization rights, and building companies around selected products and programs. The company’s activities span areas including oncology, dermatology, rare diseases and immunology. Its portfolio has included marketed dermatology medicines such as Qbrexza, Amzeeq and Zilxi, as well as investigational therapies at various stages of development.
Featured Articles
- Five stocks we like better than Fortress Biotech
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Fortress Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fortress Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
